What Is Unicycive Therapeutics, Inc. (UNCY) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Unicycive Therapeutics, Inc.'s intrinsic value is estimated at $4.32, presenting a divided outlook at the current price of $5.27. With a median implied return of -18.0% across a split 1–1 (bull–bear) consensus, the model spread of +155.8% underscores analytical uncertainty. Notably, Regime Cross sees the most upside at +59.9% (fair value: $8.42), while ML-RIV is the most conservative at -95.9% ($0.22). The spread between these extremes — +155.8% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About UNCY?
2 of 13 models are currently active for UNCY. Of these, 1 model suggests upside while 1 model suggests overvaluation. Taken together, their median fair value for UNCY is $4.32 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →
How Does UNCY Rank in Biotechnology?
Among 625 Biotechnology stocks, UNCY ranks #449 by Quality of Company score. CirclFi's QOC score of 4.5/10 evaluates 32 fundamental signals. A score of 4.5 reflects mixed fundamentals.
See all Most Undervalued Biotechnology Stocks →
As a life sciences company, Unicycive Therapeutics, Inc. operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating UNCY should weigh these sector-specific dynamics alongside our model-derived fair values.
Is UNCY a Value Trap?
CirclFi's Value Trap algorithm assigns UNCY a score of 42/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
2 of 13 models are active for Unicycive Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Unicycive Therapeutics, Inc.'s fundamental quality profile registers 4.5/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +155.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every UNCY valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across UNCY's 2 active models, average confidence is 49%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad